Overview

Long-term Extension of RECOVER- Long-term Effect of the 24h Transdermal Delivery of Rotigotine in Subjects With Idiopathic Parkinson's Disease

Status:
Terminated

Trial end date:
2009-05-01

Target enrollment:

Participant gender:

Summary

The objective of this open-label extension is to assess the long-term effect of the 24-hour transdermal delivery of rotigotine on motor function, sleep quality, and nocturnal and non-motor symptoms of Parkinson's disease. The long-term safety and tolerability of the rotigotine transdermal patch will also be evaluated.

Phase:

Phase 3

Details

Lead Sponsor:

UCB Pharma

Treatments:

N 0437
Rotigotine